MBX
MBX Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$62.91
−1.53%0
Insider buys (3m)
1
Insider sells (3m)
-$24.3K
Net value (3m)
+42.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 5, 2026 | Azoulay Salomon · officer: Chief Medical Officer | Sale | 370 | $66 |
| Aug 4, 2026 | Hoerter Steven L. · director, officer: President and CEO | A-Award | 331,000 | $64 |
| Aug 4, 2026 | Hoerter Steven L. · director, officer: President and CEO | A-Award | 71,000 | $0.00 |
| Aug 4, 2026 | Smither John W · officer: Chief Financial Officer | A-Award | 130,000 | $64 |
| Aug 4, 2026 | Smither John W · officer: Chief Financial Officer | A-Award | 28,000 | $0.00 |
| Jun 5, 2026 | Heron Patrick J · director, 10 percent owner: | A-Award | 12,500 | $31 |
| Jun 5, 2026 | Mathers Edward T · director | A-Award | 12,500 | $31 |
| Jun 5, 2026 | Pescovitz Ora H. · director | A-Award | 12,500 | $31 |
| Jun 5, 2026 | Aynechi Tiba · director | A-Award | 12,500 | $31 |
| Jun 5, 2026 | Ryder Steven · director | A-Award | 12,500 | $31 |
| Jun 5, 2026 | Hoerter Steven L. · director | A-Award | 12,500 | $31 |
| Jun 5, 2026 | Stelzer Laurie · director | A-Award | 12,500 | $31 |
| May 11, 2026 | Azoulay Salomon · officer: Chief Medical Officer | Sale | 55,000 | $38 |
| May 11, 2026 | Azoulay Salomon · officer: Chief Medical Officer | Sale | 15,003 | $38 |
| May 11, 2026 | Azoulay Salomon · officer: Chief Medical Officer | M-Exempt | 15,003 | $16 |
| May 11, 2026 | Azoulay Salomon · officer: Chief Medical Officer | M-Exempt | 55,000 | $10 |
| May 8, 2026 | Hawryluk P. Kent · director, officer: President & CEO | Sale | 607 | $30 |
| May 8, 2026 | Azoulay Salomon · officer: Chief Medical Officer | Sale | 231 | $30 |
| May 4, 2026 | Hoerter Steven L. · director | A-Award | 74,249 | $30 |
| May 4, 2026 | Hoerter Steven L. · director | A-Award | 11,938 | $0.00 |
| Apr 22, 2026 | Hoerter Steven L. · director | A-Award | 33,751 | $25 |
| Apr 22, 2026 | Hoerter Steven L. · director | A-Award | 0 | $27 |
| Mar 16, 2026 | Hawryluk P. Kent · director, officer: President & CEO | Purchase | 18,500 | $28 |
| Feb 27, 2026 | Hawryluk P. Kent · director, officer: President & CEO | M-Exempt | 28,768 | $16 |
| Feb 3, 2026 | Azoulay Salomon · officer: Chief Medical Officer | A-Award | 70,000 | $39 |
| Feb 3, 2026 | Hawryluk P. Kent · director, officer: President & CEO | A-Award | 164,500 | $39 |
| Feb 3, 2026 | Hawryluk P. Kent · director, officer: President & CEO | A-Award | 35,250 | $0.00 |
| Feb 3, 2026 | Bartram Richard · officer: Chief Financial Officer | A-Award | 15,000 | $0.00 |
| Feb 3, 2026 | Bartram Richard · officer: Chief Financial Officer | A-Award | 70,000 | $39 |
| Feb 3, 2026 | Azoulay Salomon · officer: Chief Medical Officer | A-Award | 15,000 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 79Increased 105Reduced 103Sold out 21
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | Unchanged | 6,652,013 | Aug 14, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 6,652,013 | May 15, 2026 |
| FMR LLC | Increased | 5,322,885 | Aug 13, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 4,977,523 | Aug 14, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 3,637,887 | May 15, 2026 |
| NEA Management Company, LLC | Unchanged | 3,614,486 | Aug 14, 2026 |
| NEA MANAGEMENT COMPANY, LLC | Unchanged | 3,614,486 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 3,428,736 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 3,323,672 | Aug 7, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 3,191,824 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 2,941,406 | May 13, 2026 |
| FMR LLC | Increased | 2,936,684 | May 15, 2026 |
| DEEP TRACK CAPITAL, LP | Reduced | 2,757,569 | May 15, 2026 |
| Paradigm Biocapital Advisors LP | New Position | 2,508,015 | Aug 14, 2026 |
| NVP Associates, LLC | Unchanged | 2,136,335 | Aug 7, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 5, 2026